AZ3146 (Mps1 Inhibitor III, AZ-3146) (CAS: 1124329-14-1) is a small molecule inhibitor of monopolar spindle 1 (Mps1), a protein involved in the regulation of mitotic checkpoint signaling and cell division. It has been investigated as a potential therapeutic agent for cancer, particularly in combination with other chemotherapeutic agents.
Chemical name: 3-(3-Cyclopropyl-5-(2-(1H-pyrazol-4-yl)-5-(trifluoromethyl)pyridin-4-yl)-1H-pyrazol-1-yl)propanenitrile
Molecular formula: C22H18F3N7
Formula weight: 449.42 g/mol
CAS No: 1124329-14-1
Top ten keywords from Google:
Synonyms:
Health benefits of this product: AZ3146 has demonstrated potential health benefits in the area of cancer research, particularly in the treatment of various types of cancer that are resistant to conventional chemotherapy. Its primary mode of action is through the inhibition of Mps1, leading to decreased tumor growth and increased apoptosis.
Potential effects: AZ3146 has demonstrated efficacy in several preclinical studies in inhibiting the activity of Mps1, leading to reduced tumor growth and increased DNA damage response. It also has potential benefits for inducing apoptosis (programmed cell death) of cancer cells and increasing the sensitivity of cancer cells to other chemotherapeutic agents. AZ3146 works by disrupting mitotic checkpoint signaling, leading to reduced tumor growth and increased apoptosis.
Product mechanism: AZ3146 works by inhibiting the activity of Mps1, a protein involved in the regulation of mitotic checkpoint signaling and cell division. Mps1 is essential for proper chromosome segregation and spindle formation during cell division. By inhibiting Mps1 activity, AZ3146 can disrupt mitotic checkpoint signaling, leading to reduced tumor growth and increased apoptosis.
Safety: AZ3146 has been evaluated in several preclinical studies and has shown promising safety and tolerability profiles. Its safety profile in humans is not well-established, although it has been extensively studied in animal models. Potential side effects may include gastrointestinal symptoms such as nausea, vomiting, and diarrhea.
Side effects: Common side effects of AZ3146 are not well-established due to its limited use in humans. However, in preclinical studies, potential side effects may include renal and hepatic toxicity, alterations in cardiovascular function, and allergic reactions. Patients should be monitored closely for these adverse events and receive appropriate medical intervention if necessary.
Dosing information: The optimal dose and dosing regimen of AZ3146 may vary depending on the patient's condition and treatment goals. In preclinical studies, doses ranging from 5 to 100 mg/kg have been evaluated for various types of cancer. Patients should follow their doctor's instructions regarding dosing, administration, and monitoring.
Conclusion: AZ3146 (Mps1 Inhibitor III, AZ-3146) (CAS: 1124329-14-1) is a small molecule inhibitor of Mps1, a protein involved in the regulation of mitotic checkpoint signaling and cell division. It has been investigated as a potential therapeutic agent for cancer, particularly in combination with other chemotherapeutic agents. Although its safety profile in humans is not well-established, it has shown promising results in preclinical studies. Researchers should follow established protocols and guidelines regarding dosing, administration, and monitoring.
